Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH2616 in advanced solid tumors
NCT06329206Phase 1Recruiting
- Sponsor
- Genhouse Bio
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GH2616 in solid tumor (advanced stage), sponsored by Genhouse Bio. Primary endpoints: Number of Participants Reporting Adverse Events (AEs) or Serious Adverse Events (SAEs) at 2 years and Dose-limiting Toxicities Incidence Count Among Study Participant at 2 years. Started Mar 2024; status: recruiting.
02
Drugs
GH2616
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06329206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329206.